Table 2

Patient`s and tumor characteristics in relation to presence of DTC in bone marrow
Characteristics Patients analyzed by IF No DTC in bone marrow N (%) DTC in bone marrow N (%) p-value* Patients analyzed by IC No DTC in bone marrow N (%) DTC in bone marrow N (%) p-value*
Tumor size
≤ 20 mm 203 118 (58) 85 (42) 0.3 60 42 (70) 18 (30) 1.0
> 20 mm 123 78 (63) 45 (37) 13 9 (69) 4 (31)
Node status
N0 184 113 (61) 71 (39) 0.5 49 35 (71) 14 (29) 0.7
N+ 133 77 (58) 56 (42) 24 16 (67) 8 (33)
NHG
1 60 30 (50) 30 (50) 17 13 (76) 4 (24)
2 181 110 (61) 71 (39) 0.12 40 24 (60) 16 (40) 0.7
3 80 51 (64) 29 (36) 14 12 (86) 2 (14)
ER status
Positive 252 145 (58) 107 (42) 0.12 60 41 (68) 19 (32) 0.8
Negative 66 45 (68) 21 (32) 11 8 (73) 3 (27)
PR status
Positive 189 110 (58) 79 (42) 0.5 53 37 (70) 16 (30) 0.8
Negative 129 80 (62) 49 (38) 18 12 (67) 6 (33)

* X2-test for two categories and X2-test for trend for three ordered categories.

Abbreviations: IF= immunofluorescence, IC=immunocytochemistry, DTC= disseminated tumor cells, N0= node negative, N+=node positive, NHG= Nottingham histological grade, ER= oestrogen receptor, PR= progesterone receptor.

Falck et al.

Falck et al. BMC Cancer 2012 12:403   doi:10.1186/1471-2407-12-403

Open Data